Table 3.
Genotype frequencies of selected SNPs for patients with CD and healthy controls
| Genotype | Patients with CD (n=54) | Healthy controls (n=50) | P value* OR (95% CI) |
| TNFα rs1800629 | |||
| GG (reference allele) | 34 (64%) | 41 (82%) | 0.03 |
| GA | 20 (37%) | 7 (14%) |
0.01
3.6 (1.37 to 9.54) |
| AA | 0 (0%) | 2 (4%) | 0.13 0.2 (0.01 to 5.20) |
| GA+AA | 20 (37%) | 9 (18%) |
0.03
2.7 (1.08 to 6.64) |
| TNFα rs1799964 | |||
| TT (reference allele) | 33 (61%) | 34 (68%) | 0.75 |
| TC | 18 (33%) | 16 (32%) | 0.89 1.2 (0.51 to 2.64) |
| CC | 3 (6%) | 0 (0%) | 0.09 7.2 (0.35 to 144.9) |
| TC+CC | 21 (39%) | 16 (32%) | 0.73 1.4 (0.60 to 3.00) |
| TNFα rs1799724 | |||
| CC (reference allele) | 45 (83%) | 43 (86%) | 0.7 |
| CT | 9 (16%) | 7 (14%) | 0.38 1.2 (0.42 to 3.59) |
| TT | 0 (0%) | 0 (0%) | NA |
| CT+TT | 9 (16%) | 7 (14%) | 0.70 1.2 (0.42 to 3.59) |
| TNFRSF1A rs4149584 | |||
| CC (reference allele) | 52 (96%) | 49 (98%) | 0.6 |
| CT | 2 (4%) | 1 (2%) | 0.60 1.9 (0.17 to 21.40) |
| TT | 0 (0%) | 0 (0%) | NA |
| CT+TT | 2 (4%) | 1 (0%) | 0.60 1.9 (0.17 to 21.40) |
| TNFRSF1A rs767455 | |||
| AA (reference allele) | 17 (31%) | 29 (58%) | 0.01 |
| AG | 22 (41%) | 19 (38%) | 0.29 2.0 (0.83 to 4.65) |
| GG | 15 (28%) | 2 (4%) |
0.01
9.2 (1.98 to 42.83) |
| AG+ GG | 37 (68%) | 21 (42%) |
0.01
3.0 (1.34 to 6.71) |
| TNFRSF1A rs4149570 | |||
| GG (reference allele) | 25 (46%) | 26 (52%) | 0.56 |
| GT | 13 (24%) | 18 (36%) | 0.18 0.75 (0.31 to 1.84) |
| TT | 16 (30%) | 7 (14%) | 0.06 2.4 (0.83 to 6.75) |
| GT+TT | 29 (54%) | 25 (50%) | 0.70 1.2 (0.56 to 2.59) |
| TNFRSF1B rs1061624 | |||
| AA (reference allele) | 13 (24%) | 27 (54%) | 0.01 |
| AG | 27 (50%) | 15 (30%) |
0.04
2.3 (1.04 to 5.22) |
| GG | 14 (26%) | 8 (16%) |
0.02
3.6 (1.21 to 10.83) |
| AG+ GG | 41 (76%) | 23 (46%) |
0.01
3.7 (1.61 to 8.53) |
| TNFRSF1B rs1061622 | |||
| TT (reference allele) | 24 (44%) | 31 (62%) | 0.07 |
| TG | 22 (41%) | 16 (32%) | 0.36 1.8 (0.77 to 4.1) |
| GG | 8 (15%) | 3 (6%) | 0.14 3.44 (0.82 to 14.4) |
| TG+GG | 30 (%) | 19 (38%) | 0.07 2.03 (0.93 to 4.47) |
| TNFRSF1B rs3397 | |||
| CC (reference allele) | 12 (22%) | 31 (62%) | 0.01 |
| CT | 31 (57%) | 15 (30%) |
0.01
3.1 (1.4 to 7.07) |
| TT | 15 (28%) | 4 (8%) |
0.01
4.4 (1.36 to 14.14) |
| CT+TT | 46 (85%) | 19 (38%) |
0.01
6.25 (2.66 to 14.69) |
Two-tailed Z test and OR analysis were used to compare between the presence of SNPs in patients with CD versus healthy controls.
*P<0.05 was considered as significance threshold.
CD, Crohn’s disease; NA, unknown residue change; SNP, single nucleotide polymorphism; TNFα, tumour necrosis factor-α.